US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nivalis Therapeutics

2.40

0.0000

Volume:- -

Turnover:- -

Market Cap:37.57M

PE:-1.18

High:2.40

Open:2.40

Low:2.40

Close:2.40

52wk High:9.35

52wk Low:2.00

Shares:15.66M

Float Shares:10.07M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0400

ROE:--

ROA:--

PB:0.76

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Nivalis Therapeutics

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.novellus.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis (CF). CF is a life-shortening genetic disease. Its lead product candidate is N91115, a small molecule that is in Phase II clinical trial, which addresses a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NVLS/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVLS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVLS\",,,,,undefined,":{"symbol":"NVLS","market":"US","secType":"STK","nameCN":"Nivalis Therapeutics","latestPrice":2.4,"timestamp":1500926400000,"preClose":2.4,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":10070000,"shares":15656000,"eps":-2.04,"marketStatus":"Delisted","change":0,"latestTime":"07-24 16:00:00 EDT","open":2.4,"high":2.4,"low":2.4,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.04,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770800400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1434513600000,"exchange":"NASDAQ","adjPreClose":2.4,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVLS\",,,,,undefined,":{"symbol":"NVLS","floatShares":10070000,"roa":"--","roe":"--","lyrEps":0,"shares":15656000,"dividePrice":0,"high":2.4,"amplitude":0,"preClose":2.4,"low":2.4,"week52Low":2,"pbRate":"0.76","week52High":9.35,"institutionHeld":0,"latestPrice":2.4,"eps":-2.04,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.04,"open":2.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVLS\",params:#limit:5,,,undefined,":[{"date":"2017-07-25","symbol":"NVLS","type":"split","dateTimestamp":1500955200000,"forFactor":4,"toFactor":1},{"date":"2017-07-25","symbol":"NVLS","newSymbol":"ALPN","type":"symbolChange","dateTimestamp":1500955200000},{"market":"US","date":"2017-07-21","symbol":"NVLS","fiscalQuarterEnding":null,"expectedEps":-0.24,"name":null,"time":"","type":"earning","dateTimestamp":1500609600000,"reportTimeType":"","actualEps":-0.18},{"market":"US","date":"2017-05-01","symbol":"NVLS","fiscalQuarterEnding":null,"expectedEps":-0.56,"name":null,"time":"","type":"earning","dateTimestamp":1493611200000,"reportTimeType":"","actualEps":-0.56},{"market":"US","date":"2017-02-13","symbol":"NVLS","fiscalQuarterEnding":null,"expectedEps":-0.55,"name":null,"time":"","type":"earning","dateTimestamp":1486962000000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVLS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVLS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.novellus.com","stockEarnings":[{"period":"1week","weight":-0.75},{"period":"1month","weight":-0.75},{"period":"3month","weight":-0.75},{"period":"6month","weight":-0.75},{"period":"1year","weight":-0.75},{"period":"ytd","weight":-0.75}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis (CF). CF is a life-shortening genetic disease. Its lead product candidate is N91115, a small molecule that is in Phase II clinical trial, which addresses a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.","exchange":"NASDAQ","name":"Nivalis Therapeutics","nameEN":"Nivalis Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NVLS\",market:\"US\",,,undefined,":null}}